Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Article Information
vol. 32 no. 9 1663-1668
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 18, 2009
- Accepted June 8, 2009
- Published in print August 28, 2009.
- Published online ahead of print June 19, 2009.
Article Versions
- Previous version (June 19, 2009 - 06:48).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2009 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Author Information
- Claus M. Larsen, MD1,
- Mirjam Faulenbach, MD2,
- Allan Vaag, MD, PHD1,3,
- Jan A. Ehses, PHD2,
- Marc Y. Donath, MD2 and
- Thomas Mandrup-Poulsen, MD, PHD1,4,5
- 1Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark;
- 2Clinic for Endocrinology and Diabetes, University Hospital Zurich, Zurich, Switzerland;
- 3University of Lund, Lund, Sweden;
- 4Core Unit for Medical Research Methodology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
- 5Karolinska Institutet, Stockholm, Sweden.
- Corresponding author: Thomas Mandrup-Poulsen, tmpo{at}hagedorn.dk.
-
C.M.L., M.F., M.Y.D., and T.M.-P. contributed equally to this study.
Statistics from Altmetric.com
Article usage
In this Issue
September 2009, 32(9)
Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
